Prioritizing parotid gland surgery: A call for the implementation of the MSRSGC classification.
MSRSGC
Milan system for reporting salivary gland cytology
TTI
fine-needle
parotid
salivary gland neoplasms (Mesh)
salivary glands
time-to-treatment (Mesh)
time-to-treatment initiation
Journal
Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
29
05
2023
received:
22
02
2023
accepted:
26
06
2023
medline:
3
11
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is developed to aid diagnosis and management of salivary gland tumors. This study evaluates the time-to-treatment initiation (TTI) for parotid gland tumors in the Netherlands and relates these to the MSRSGC classification. Subsequently, the use of the MSRSGC in the Netherlands is evaluated. Data regarding fine-needle aspiration cytology (FNAC) and histopathological resections of the parotid were gathered from the Dutch nationwide pathology data bank (PALGA). The TTI was calculated for each MSRSGC category and type of treating center. FNACs performed from 2018 to 2021 were gathered from PALGA to estimate how frequently the MSRSGC classification was applied. Median TTI in days were 86 for nondiagnostic (MSRSGC I), 75 for nonneoplastic (MSRSGC II), 65 for atypia of unknown significance (AUS) (MSRSGC III), 89 for benign (MSRSGC IVa), 52 for salivary gland neoplasm of unknown malignant potential (SUMP) (MSRSGC IVb), 31 for suspected malignant (MSRSGC V), and 30 for malignant (MSRSGC VI) categories. Significant variation in the TTI between the types of treating centers was found for the nondiagnostic, nonneoplastic, AUS, SUMP, and suspected malignant categories. In the first 3 years after the introduction of the MSRSGC, the pathologist stated the MSRSGC classification in 6.4% of all reports. The median TTI for most categories is long, and there is significant interhospital variation in TTI. Preoperative risk stratification and treatment prioritization in parotid gland surgery in the Netherlands should be improved. The MSRSGC could contribute to this. Until 2021, the MSRSGS classification was implemented on a limited scale in the Netherlands.
Sections du résumé
BACKGROUND
The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is developed to aid diagnosis and management of salivary gland tumors. This study evaluates the time-to-treatment initiation (TTI) for parotid gland tumors in the Netherlands and relates these to the MSRSGC classification. Subsequently, the use of the MSRSGC in the Netherlands is evaluated.
METHODS
Data regarding fine-needle aspiration cytology (FNAC) and histopathological resections of the parotid were gathered from the Dutch nationwide pathology data bank (PALGA). The TTI was calculated for each MSRSGC category and type of treating center. FNACs performed from 2018 to 2021 were gathered from PALGA to estimate how frequently the MSRSGC classification was applied.
RESULTS
Median TTI in days were 86 for nondiagnostic (MSRSGC I), 75 for nonneoplastic (MSRSGC II), 65 for atypia of unknown significance (AUS) (MSRSGC III), 89 for benign (MSRSGC IVa), 52 for salivary gland neoplasm of unknown malignant potential (SUMP) (MSRSGC IVb), 31 for suspected malignant (MSRSGC V), and 30 for malignant (MSRSGC VI) categories. Significant variation in the TTI between the types of treating centers was found for the nondiagnostic, nonneoplastic, AUS, SUMP, and suspected malignant categories. In the first 3 years after the introduction of the MSRSGC, the pathologist stated the MSRSGC classification in 6.4% of all reports.
CONCLUSIONS
The median TTI for most categories is long, and there is significant interhospital variation in TTI. Preoperative risk stratification and treatment prioritization in parotid gland surgery in the Netherlands should be improved. The MSRSGC could contribute to this. Until 2021, the MSRSGS classification was implemented on a limited scale in the Netherlands.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
701-707Informations de copyright
© 2023 The Authors. Cancer Cytopathology published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
El-Naggar AK, Centre international de recherche sur le c. WHO classification of head and neck tumours. International Agency for Research on Cancer; 2017.
Liu CC, Jethwa AR, Khariwala SS, Johnson J, Shin JJ. Sensitivity, specificity, and posttest probability of parotid fine-needle aspiration: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2016;154(1):9-23. doi:10.1177/0194599815607841
Faquin WC, Rossi ED, Baloch ZW, Field A, Katabi N, Wenig BM. The Milan System for Reporting Salivary Gland Cytopathology. Springer; 2018:chap 1-9.
Viswanathan K, Sung S, Scognamiglio T, Yang GCH, Siddiqui MT, Rao RA. The role of the Milan System for Reporting Salivary Gland Cytopathology: a 5-year institutional experience. Cancer Cytopathol. 2018;126(8):541-551. doi:10.1002/cncy.22016
Savant D, Jin C, Chau K, et al. Risk stratification of salivary gland cytology utilizing the Milan system of classification. Diagn Cytopathol. 2019;47(3):172-180. doi:10.1002/dc.24063
Dubucs C, Basset C, D'Aure D, Courtade-Saidi M, Evrard SM. A 4-year retrospective analysis of salivary gland cytopathology using the Milan System for reporting salivary gland cytology and ancillary studies. Cancers. 2019;11(12):1912. doi:10.3390/cancers11121912
Mazzola F, Gupta R, Luk PP, Palme C, Clark JR, Low TH. The Milan System for Reporting Salivary Gland Cytopathology-proposed modifications to improve clinical utility. Head Neck. 2019;41(8):2566-2573. doi:10.1002/hed.25732
Wu HH, Alruwaii F, Zeng BR, Cramer HM, Lai CR, Hang JF. Application of the Milan System for Reporting Salivary Gland Cytopathology: a retrospective 12-year bi-institutional study. Am J Clin Pathol. 2019;151(6):613-621. doi:10.1093/ajcp/aqz006
Song SJ, Shafique K, Wong LQ, LiVolsi VA, Montone KT, Baloch Z. The utility of the Milan System as a risk stratification tool for salivary gland fine needle aspiration cytology specimens. Cytopathology. 2019;30(1):91-98. doi:10.1111/cyt.12642
Choy KCC, Bundele MM, Li H, Fu EW, Rao NCL, Lim MY. Risk stratification of fine-needle aspiration cytology of parotid neoplasms based on the Milan System-experience from a tertiary center in Asia. Head Neck. 2019;41(9):3125-3132. doi:10.1002/hed.25804
Chen YA, Wu CY, Yang CS. Application of the Milan System for Reporting Salivary Gland Cytopathology: a retrospective study in a tertiary institute. Diagn Cytopathol. 2019;47(11):1160-1167. doi:10.1002/dc.24279
Lee JJL, Tan HM, Chua DYS, Chung JGK, Nga ME. The Milan System for Reporting Salivary Gland Cytology: a retrospective analysis of 1384 cases in a tertiary Southeast Asian institution. Cancer Cytopathol. 2020;128(5):348-358. doi:10.1002/cncy.22245
Mazzola F, Tomasoni M, Mocellin D, et al. A multicenter validation of the revised version of the Milan system for reporting salivary gland cytology (MSRSGC). Oral Oncol. 2020;109:104867. doi:10.1016/j.oraloncology.2020.104867
Reerds STH, Van Engen-Van Grunsven ACH, van den Hoogen FJA, Takes RP, Marres HAM, Honings J. Accuracy of parotid gland FNA cytology and reliability of the milan system for reporting salivary gland cytopathology in clinical practice. Cancer Cytopathol. 2021;129(9):719-728. doi:10.1002/cncy.22435
Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29(1):19-24. doi:10.1155/2007/971816
Eveson J, Auclair PL, Gnepp DR, El Naggar AK. Tumours of the salivary gland. In: Barnes L, Eveson JW, Reichart P, Sidransky D, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. IARC; 2005:164.
Morse E, Fujiwara RJT, Judson B, Mehra S. Treatment times in salivary gland cancer: national patterns and association with survival. Otolaryngol Head Neck Surg. 2018;159(2):283-292. doi:10.1177/0194599818758020
Haderlein M, Scherl C, Semrau S, et al. High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype. Head Neck. 2016;38(suppl 1):E2041-E2048. doi:10.1002/hed.24375
Park W, Bae H, Park MH, et al. Risk of high-grade malignancy in parotid gland tumors as classified by the Milan System for Reporting Salivary Gland Cytopathology. J Oral Pathol Med. 2019;48(3):222-231. doi:10.1111/jop.12816
Shafique K, Zhang PJ, Montone KT, Song S, Livolsi VA, Baloch Z. Pathologic grading of mucoepidermoid carcinomas of the salivary gland and its effect on clinicopathologic follow-up: an institutional experience. Hum Pathol. 2020;98:89-97. doi:10.1016/j.humpath.2020.02.001
Lee DY, Song S, Yang SK, et al. Prediction of malignancy in salivary gland tumors by a new cytology reporting system. Ear Nose Throat J. 2020;100(10):145561320927912. doi:10.1177/0145561320927912
Song H, Fang F, Valdimarsdottir U, et al. Waiting time for cancer treatment and mental health among patients with newly diagnosed esophageal or gastric cancer: a nationwide cohort study. BMC Cancer. 2017;17(1):2. doi:10.1186/s12885-016-3013-7
Derrett S, Paul C, Morris JM. Waiting for elective surgery: effects on health-related quality of life. Int J Qual Health Care. 1999;11(1):47-57. doi:10.1093/intqhc/11.1.47
Oudhoff JP, Timmermans DR, Knol DL, Bijnen AB, van der Wal G. Waiting for elective general surgery: impact on health related quality of life and psychosocial consequences. BMC Publ Health. 2007;7(1):164. doi:10.1186/1471-2458-7-164
Murphy CT, Galloway TJ, Handorf EA, et al. Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States. J Clin Oncol. 2016;34(2):169-178. doi:10.1200/JCO.2015.61.5906